Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in previously treated hepatocellular carcinoma
NCT03419897Phase 2Completed
- Sponsor
- BeiGene
- Start
- Apr 2018
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by BeiGene. Started Apr 2018; status: completed.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03419897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03419897.